203 related articles for article (PubMed ID: 29858134)
21. Focal radiotherapy as focal therapy of prostate cancer.
Kovács G; Cosset JM; Carey B
Curr Opin Urol; 2014 May; 24(3):231-5. PubMed ID: 24637315
[TBL] [Abstract][Full Text] [Related]
22. [Permanent implant prostate cancer brachytherapy].
Cosset JM; Flam T; Thiounn N; Pontvert D; Pierrat N; Vallancien G; Chauveinc L
Cancer Radiother; 2008 Nov; 12(6-7):503-11. PubMed ID: 18829365
[TBL] [Abstract][Full Text] [Related]
23. Controversies in prostate cancer radiotherapy: consensus development.
Lukka H; Warde P; Pickles T; Morton G; Brundage M; Souhami L;
Can J Urol; 2001 Aug; 8(4):1314-22. PubMed ID: 11564274
[TBL] [Abstract][Full Text] [Related]
24. Early observed transient prostate-specific antigen elevations on a pilot study of external beam radiation therapy and fractionated MRI guided high dose rate brachytherapy boost.
Singh AK; Guion P; Susil RC; Citrin DE; Ning H; Miller RW; Ullman K; Smith S; Crouse NS; Godette DJ; Stall BR; Coleman CN; Camphausen K; Ménard C
Radiat Oncol; 2006 Aug; 1():28. PubMed ID: 16914054
[TBL] [Abstract][Full Text] [Related]
25. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
[TBL] [Abstract][Full Text] [Related]
26. Brachytherapy: current status and future strategies -- can high dose rate replace low dose rate and external beam radiotherapy?
Morton GC; Hoskin PJ
Clin Oncol (R Coll Radiol); 2013 Aug; 25(8):474-82. PubMed ID: 23727431
[TBL] [Abstract][Full Text] [Related]
27. [Review on the effectiveness of prostate cancer brachytherapy].
Inciūra A; Jarusevicus L; Vaiciūnas K; Juozaityte E
Medicina (Kaunas); 2009; 45(8):660-71. PubMed ID: 19773626
[TBL] [Abstract][Full Text] [Related]
28. External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer.
Strom TJ; Hutchinson SZ; Shrinath K; Cruz AA; Figura NB; Nethers K; Biagioli MC; Fernandez DC; Heysek RV; Wilder RB
Int Braz J Urol; 2014; 40(4):474-83. PubMed ID: 25251952
[TBL] [Abstract][Full Text] [Related]
29. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
[TBL] [Abstract][Full Text] [Related]
30. High dose rate brachytherapy for prostate cancer.
Hoskin P
Cancer Radiother; 2008 Nov; 12(6-7):512-4. PubMed ID: 18755623
[TBL] [Abstract][Full Text] [Related]
31. Brachytherapy for prostate cancer: summary of American Brachytherapy Society recommendations.
Nag S
Semin Urol Oncol; 2000 May; 18(2):133-6. PubMed ID: 10875454
[TBL] [Abstract][Full Text] [Related]
32. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
[TBL] [Abstract][Full Text] [Related]
33. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
Nieder AM; Porter MP; Soloway MS
J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
[TBL] [Abstract][Full Text] [Related]
34. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution.
Todor DA; Barani IJ; Lin PS; Anscher MS
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392
[TBL] [Abstract][Full Text] [Related]
35. Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer.
Zaorsky NG; Den RB; Doyle LA; Dicker AP; Hurwitz MD
Expert Rev Med Devices; 2013 Nov; 10(6):751-63. PubMed ID: 24195459
[TBL] [Abstract][Full Text] [Related]
36. [Prostate brachytherapy: indications and outcomes].
Hennequin C; Cormier L; Richaud P; Bastide C; Beuzeboc P; Fromont G; Mongiat-Artus P; Peyromaure M; Ploussard G; Renard-Penna R; Rozet F; Soulié M; Salomon L;
Prog Urol; 2013 May; 23(6):378-85. PubMed ID: 23628094
[TBL] [Abstract][Full Text] [Related]
37. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
[TBL] [Abstract][Full Text] [Related]
38. Long-term results of permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003.
Cosset JM; Flam T; Belin L; Thiounn N; Pierrat N; Pontvert D; Wakil G; Savignoni A; Chauveinc L
Cancer Radiother; 2016 Jun; 20(4):261-7. PubMed ID: 27318554
[TBL] [Abstract][Full Text] [Related]
39. Management of local relapse after prostate cancer radiotherapy: Surgery or radiotherapy?
Hennequin C; Hannoun-Lévi JM; Rozet F
Cancer Radiother; 2017 Oct; 21(6-7):433-436. PubMed ID: 28890088
[TBL] [Abstract][Full Text] [Related]
40. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out.
D'Amico AV; Coleman CN
J Clin Oncol; 1996 Jan; 14(1):304-15. PubMed ID: 8558212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
